NCT07744984Completed
The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab
Home OCT-Guided Management of Neovascular Age Related Macular Degeneration: Outcomes and Insight After Switch to Faricimab for One Year
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye. However, some patients do not respond well to their current treatment and need to switch to a different medication. The purpose of this study is to evaluate whether using a home optical coherence tomography (Home OCT) device can improve the management of patients with neovascular AMD who are switching to faricimab treatment after an insufficient response to previous therapy. The Home OCT device allows participants to perform retinal scans at home several times a week. These scans are securely transmitted to the study team, allowing physicians to monitor changes in the retina more frequently than with routine clinic visits alone. Participants will continue to receive the standard medical care determined by their treating retina specialist, including clinic visits, eye examinations, retinal imaging, and intravitreal injections. The Home OCT device will provide additional information to help detect changes in disease activity between clinic visits. If the scans suggest worsening of the condition, participants may be asked to return for an earlier evaluation. The study aims to determine whether frequent home monitoring can identify treatment response sooner and support more personalized treatment decisions. The study will also collect information on the effectiveness of faricimab in routine clinical practice after switching from previous anti-VEGF therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 12 (actual)
- First submitted
- 29 Jul 2026
- Start date
- 3 Jul 2024
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Rabin Medical Center
- Diseases
- Macular degeneration
- NCT number
- NCT07744984
What you commit to
- Study type: Observational
- Participants enrolled: 12
- From 3 Jul 2024 to the primary completion date, 1 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any concurrent ocular condition precluding acquisition of OCT images (eg, severe blepharoptosis, corneal opacification, cataract etc) in the study eye
Other illness
- Patients with any other retinal disease in the study eye requiring steroidal or anti-VEGF injections (anti-VEGF injections during the study period must be for nvAMD).
Who the study is looking for
- Patients at least 55 years of age.
- Visual Acuity of 20/320 or better in the study eye.
- Diagnosis of active nvAMD that was treated with at least 3 consecutive anti-VEGF injections.
- Patients are meeting the standard care criteria to switch to a second line drug.
- Patients are able and willing to conduct daily OCT self-imaging at home for the duration of the study.
- Patient signing a consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rabin Medical Center Coordinator of this site? Confirm its status | Petah Tikva | Israel | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.